A resurrection of 7-MEOTA: a comparison with tacrine.

  title={A resurrection of 7-MEOTA: a comparison with tacrine.},
  author={O. Soukup and D. Jun and J. Zdarova-Karasova and J. Patocka and K. Musilek and J. Kor{\'a}be{\vc}n{\'y} and J. Krů{\vs}ek and M. Kaniakov{\'a} and V. Sepsova and J. Mand{\'i}kov{\'a} and F. Trejtnar and M. Pohanka and L. Drtinov{\'a} and M. Pavl{\'i}k and G. Tobin and K. Ku{\vc}a},
  journal={Current Alzheimer research},
  volume={10 8},
Alzheimer´s disease (AD) is a progressive neurodegenerative dementia which currently represents one of the biggest threats for the human kind. The cure is still unknown and various hypotheses (cholinergic, amyloidal, oxidative, vascular etc.) are investigated in order to understand the pathophysiology of the disease and on this basis find an effective treatment. Tacrine, the first approved drug for the AD disease treatment, has been reported to be a multitargeted drug, however it was withdrawn… Expand
Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy
Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors
Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer's disease treatment.